Barrington Research Raises LeMaitre Vascular (NASDAQ:LMAT) Price Target to $120.00

08 May 2026, 03:57 by Jessica Moore · The Cerbat Gem

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) had its price objective hoisted by Barrington Research from $105.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Barrington Research’s price objective would suggest a potential upside of 11.20% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on LMAT. Wells Fargo & Company raised their price target on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Freedom Capital raised LeMaitre Vascular to a “hold” rating in a research note on Tuesday, March 31st. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings raised LeMaitre Vascular from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, March 10th. Finally, Zacks Research raised LeMaitre Vascular from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $112.60.

Get Our Latest Stock Analysis on LMAT

LeMaitre Vascular Stock Down 2.1%

Shares of LeMaitre Vascular stock opened at $107.91 on Wednesday. The stock has a 50-day moving average price of $110.00 and a 200 day moving average price of $94.48. The company has a market cap of $2.47 billion, a P/E ratio of 39.82, a P/E/G ratio of 3.06 and a beta of 0.60. The company has a current ratio of 14.32, a quick ratio of 10.95 and a debt-to-equity ratio of 0.42. LeMaitre Vascular has a 1 year low of $78.35 and a 1 year high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.02. LeMaitre Vascular had a return on equity of 15.36% and a net margin of 24.35%.The firm had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same period in the prior year, the business earned $0.48 EPS. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. As a group, analysts expect that LeMaitre Vascular will post 3 EPS for the current fiscal year.

Insider Activity

In other LeMaitre Vascular news, insider Trent G. Kamke sold 1,044 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The stock was sold at an average price of $110.29, for a total value of $115,142.76. Following the sale, the insider owned 6,677 shares of the company’s stock, valued at $736,406.33. This trade represents a 13.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David B. Roberts sold 8,464 shares of the firm’s stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $106.80, for a total value of $903,955.20. Following the completion of the sale, the director directly owned 17,979 shares in the company, valued at $1,920,157.20. This trade represents a 32.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 215,438 shares of company stock valued at $23,062,911. Insiders own 7.40% of the company’s stock.

Institutional Trading of LeMaitre Vascular

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in LeMaitre Vascular by 1.4% in the 4th quarter. Vanguard Group Inc. now owns 1,622,033 shares of the medical instruments supplier’s stock valued at $131,547,000 after buying an additional 21,946 shares during the last quarter. Conestoga Capital Advisors LLC grew its holdings in LeMaitre Vascular by 3.6% in the 1st quarter. Conestoga Capital Advisors LLC now owns 1,476,813 shares of the medical instruments supplier’s stock valued at $161,224,000 after buying an additional 51,825 shares during the last quarter. First Trust Advisors LP grew its holdings in LeMaitre Vascular by 13.4% in the 4th quarter. First Trust Advisors LP now owns 940,140 shares of the medical instruments supplier’s stock valued at $76,245,000 after buying an additional 111,193 shares during the last quarter. State Street Corp grew its holdings in LeMaitre Vascular by 0.8% in the 4th quarter. State Street Corp now owns 806,993 shares of the medical instruments supplier’s stock valued at $65,447,000 after buying an additional 6,130 shares during the last quarter. Finally, Congress Asset Management Co. grew its holdings in LeMaitre Vascular by 5.8% in the 4th quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier’s stock valued at $59,392,000 after buying an additional 40,065 shares during the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

Positive Sentiment: Several firms raised price targets and issued upbeat notes, supporting upside. Barrington raised its target to $120 and reiterates an outperform view. Barrington Research Raises Target
Positive Sentiment: Citizens JMP lifted its target to $127 and kept a market‑outperform stance, the most bullish target among recent updates. Citizens JMP Raises Target
Positive Sentiment: Zacks upgraded LMAT to a Rank #2 (Buy) and published a bullish piece highlighting growth characteristics that could attract investors. LeMaitre (LMAT) Upgraded to Buy: Here’s Why
Positive Sentiment: Company Q1 results beat EPS estimates modestly and management gave FY‑2026 EPS guidance of $2.93–$3.08 (Q2 guidance $0.79–$0.84), supporting higher analyst valuations around ~$118 consensus. Strong margins and revenue growth underpinned the upbeat notes. US$118 – That’s What Analysts Think…
Positive Sentiment: LeMaitre declared a quarterly dividend ($0.25/share), modestly supportive for income-minded investors and signaling confidence in cash flow. (Ex‑dividend May 21.)
Neutral Sentiment: Management will present at the Bank of America Healthcare Conference on May 13 — an opportunity for investor Q&A but not a guaranteed catalyst. LeMaitre to Present at the Bank of America Healthcare Conference
Neutral Sentiment: Wells Fargo raised its target to $104 but kept an Equal Weight rating — the move is less bullish than other shops and reflects mixed analyst views on near‑term upside. Wells Fargo Target Raise
Neutral Sentiment: The Q1 earnings call transcript and deep‑dive coverage outline drivers — Artegraft expansion and pricing helped margins — but also note cautious market reaction; useful reading for investors deciding whether margins and growth justify the higher multiples. Q1 2026 Earnings Call Transcript LMAT Q1 deep dive…
Negative Sentiment: Despite the positive notes, some coverage and market participants remain cautious about sustainability of margin gains and valuation (mixed analyst ratings persist), which likely contributed to the share pullback today.

LeMaitre Vascular Company Profile

(Get Free Report)

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.